Indian Stock Market News | BSE/NSE Sensex Updates | Equity Market Highlights

Market Highlights

Get the latest Indian stock / share market highlights, BSE/NSE stock news, business research reports & details - updated daily by Money Times.

June 19, 2025

Daily Morning Report Date: 19.06.2025
NIFTY OUTLOOK: 24812.05 FII: +890.93 cr DII: +1091.34 cr
As discussed yesterday, market behaviour remained on expected lines. Nifty failed to sustain above 24917 and slipped, hovering near the support of 24789 throughout the day, finally closing at 24812.05.
A gravestone doji-type candlestick pattern appeared on the daily chart, indicating selling pressure at higher levels. If this pressure persists, a decisive breakdown below yesterday’s low of 24750 may drag Nifty down to 24687–24627. Further supply may lead to a test of 24565.
However, on the upside, 24873 to 24937 may act as immediate resistance. A breakout above these levels and sustained trade may push Nifty towards 24997 to 25060.
Bank Nifty OUTLOOK:
SPOT: 55828.75 PCR: 0.73 Max CE OI: 56000 Max PE OI: 56000
On 18th June 2025, Bank Nifty closed at 55828.75, up 0.21% from the previous day. The index moved 421.80 points during the session, making a high of 55933.60 and a low of 55511.80.
Technical View on Daily Chart:
Key support and resistance levels are 55100 and 56050, respectively.
Today’s Technical Strategy:
Go Long above 56100 with a stop loss of 55900 and target of 56400
Go Short below 55600 with a stop loss of 55800 and target of 55300
The Relative Strength Index (RSI) is at 53.80. A reading below 30 is considered oversold, and above 70 is overbought.
Bank Nifty Day SMA Analysis:
Bank Nifty is trading above 7 out of 8 SMAs (5, 20, 30, 50, 100, 150, 200 Day) and below 1 out of 8 SMAs (10 Day).
One bullish candlestick pattern was identified in Bank Nifty.
• Short line uptrend
Macros.
1.Dollar index @ 98.64
2.Vix @ 20.14
3.Crude @ 76.51
4.10 years US bond yield @ 4.396
Note:
A Wall Street Journal report stated that President Trump informed senior aides late Tuesday that he had approved a strike on Iran but paused the action to see if Tehran would pull back from its nuclear ambitions.
On the economic front, the Federal Reserve kept its key policy rate unchanged at 4.25%–4.50% on Wednesday, while maintaining expectations for two quarter-point rate cuts later this year. Chair Jerome Powell noted that inflation in goods is likely to rise this summer as recent tariffs imposed by President Trump start impacting consumer prices.
The Fed now projects a slower pace of easing, with rates expected to fall to 3.6% in 2026 (up from 3.4%) and to 3.4% in 2027 (up from 3.1%). The policy statement was balanced—while rate cuts are on the table, inflation projections are higher than earlier.
Conclusion:
The potential U.S. involvement in the Iran conflict over the weekend could trigger panic in equity and energy markets. Crude oil prices may surge towards $82–85 if tensions escalate. The Fed’s policy, though balanced, indicates a 50 bps cut in 2025, which appears unlikely. We need to stay cautious.
Contributed by
Ashok bhandari : INH000019549
-------------------------------------xxxxxxx-------------------------------------------------------------------xxxxxxx---------------------------------
Tata Elxsi and Infineon partner to develop advanced EV solutions for Indian market, accelerating EV adoption.
@beatthestreet10
ABBOTT INDIA: Signs deal with MSD to distribute Sitagliptin-based diabetes drugs in India.
Enhances Abbott’s chronic care portfolio and expands diabetic treatment access.
MSD to continue manufacturing; Abbott to lead nationwide distribution.
@beatthestreet10
METROPOLIS: Appoints Dr. Monika Prabhakar as Group Head – Lab Operations, effective June 19, 2025.
She brings 28 years of experience, including senior roles at Dr. Lal Pathlabs and Metropolis.
Her expertise in diagnostics and lab quality signals renewed focus on operational excellence.
@beatthestreet10
GLENMARK PHARMA: HDFC MF BOUGHT ADDITIONAL 0.13 % STAKE ON 17 JUNE VIA OPEN MARKET
STAKE INCREASED TO 5.07 % FROM 4.94 % EARLIER
GETALONG ENTERPRISE : PROMOTER BOUGHT 2.09 % STAKES ON 5,18 th JUNE VIA OPEN MARKET
PAYTM: Paytm files compounding plea with RBI to resolve ₹611 crore FEMA case.
Seeks relief to avoid ED action; requests ED to pause adjudication. Compounding lets firms admit violations and settle with a fine. RBI has full discretion. No response yet from Paytm or RBI to email queries.
AARTI PHARMALABS : PROMOTER SOLD 0.08 % STAKES ON 16,17 th JUNE VIA OPEN MARKET
KROSS LTD : PROMOTER BOUGHT 0.04 % STAKES ON 17 th JUNE VIA OPEN MARKET
SURAKSHA DIAGNOSTIC : PROMOTER BOUGHT 0.01 % STAKES ON 18 th JUNE VIA OPEN MARKET
TATA TECHNOLOGIES: Co. selected as Strategic Engineering Supplier by Volvo Cars.
Partnership upgrade includes product and software engineering. Work to be delivered from India, Sweden, Romania, and Poland. CEO calls it validation of global capabilities.
Positive — boosts global visibility, may drive revenue growth and attract other OEM clients.
GOVT INVITES EOI FROM INDIAN COS FOR DVPT OF ADVANCED MEDIUM COMBAT AIRCRAFT
GOVERNMENT SAYS Applicant For AMCA Order, May Be A Single Co, JV Or A Consortium Of Companies
Eol For Dvpt Of Advanced Medium Combat Aircraft To Be Submitted By August 16, 2025
Pre-Eol Meeting For Parties Buying Eol Document, Will Be In 1st Week of July
AARTI IND: DGTR initiates anti-dumping probe on EU imports of Para Nitro Toluene.
Aims to counter unfair pricing and protect Indian makers. AARTI IND is a key domestic producer.
Positive — possible import duties may boost margins and competitiveness for the company in the domestic market.
GUJARAT FLUOROCHEMICALS: DGTR begins sunset review of anti-dumping duty on fluoroelastomer imports from China.
GUJARAT FLUOROCHEMICALS is a major domestic producer. Review assesses need for duty extension.
GARWARE TECHNICAL: DGTR launches anti-dumping probe on TPU-based protection film from China.
GARWARE TECHNICAL is a key domestic player. Investigation targets unfair pricing to protect Indian industry.
MARKSANS PHARMA: UK subsidiary Relonchem gets UKMHRA nod for Oxybutynin Oral Solution.
Relonchem Ltd receives UK approval for Oxybutynin Hydrochloride 2.5mg/5ml Oral Solution.
Expands presence in urology segment and strengthens portfolio in regulated markets including India, UK, and USA.
IKS ; 30.08 Lk Shares (1.75% Eq) Worth *499 Cr Change Hands At 1,659/sh
PURVANKARA UP 7 % ON 270 CR ORDER WIN

First

Last